Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 22, 2008, Pages 5875-5878

  Nomura, Daniel K ^a   Hudak, Carolyn S S ^a   Ward, Anna M ^a   Burston, James J ^b   Issa, Roger S ^a   Fisher, Karl J ^a   Abood, Mary E ^c   Wiley, Jenny L ^b   Lichtman, Aron H ^b   Casida, John E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

2 Arachidonoylglycerol; Arachidonic acid; Monoacylglycerol lipase inhibitors

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROLYSIS; IC 50; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ARACHIDONIC ACID; ARACHIDONIC ACIDS; BRAIN; CELL MEMBRANE; GLYCERIDES; INHIBITORY CONCENTRATION 50; MICE; MOLECULAR STRUCTURE; MONOACYLGLYCEROL LIPASES; ORGANOPHOSPHORUS COMPOUNDS; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; SULFUR COMPOUNDS;

MUS;

EID: 55249090375     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.007     Document Type: Article

References (27)

1. Piomelli D. Nat. Rev. Neurosci. 4 (2003) 873
2. Di Marzo V., and Petrosino S. Curr. Opin. Lipidol. 18 (2007) 129
3. Ahn K., McKinney M.K., and Cravatt B.F. Chem. Rev. 108 (2008) 1687
4. Blankman J.L., Simon G.M., and Cravatt B.F. Chem. Biol. 14 (2007) 1347
5. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., and Lichtman A.H. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9371
6. Quistad G.B., Klintenberg R., Caboni P., Liang S.N., and Casida J.E. Toxicol. Appl. Pharmacol. 211 (2006) 78
7. Nomura D.K., Blankman J.L., Simon G.M., Fujioka K., Issa R.S., Ward A.M., Cravatt B.F., and Casida J.E. Nat. Chem. Biol. 4 (2008) 373
8. Segall Y., Quistad G.B., Sparks S.E., Nomura D.K., and Casida J.E. Toxicol. Sci. 76 (2003) 131
9. Martin B.R., Beletskaya I., Patrick G., Jefferson R., Winckler R., Deutsch D.G., Di Marzo V., Dasse O., Mahadevan A., and Razdan R.K. J. Pharmacol. Exp. Ther. 294 (2000) 1209
10. In a representative reaction, ethyl n-dodecylchlorophosphonate (Björkling, F.; Dahl, A.; Patkar, S.; Zundel, M. Bioorg. Med. Chem. 1994, 2, 697-705) (0.63 mmol) in methylene chloride (4 ml) was added to 4-cyanophenol (0.46 mmol) and triethylamine (100 μl) in methylene chloride (2 ml). The mixture was stirred for 20 h at room temperature, diluted with ethyl acetate (20 ml), filtered through silica gel, and purified on a silica gel column using 30% ethyl acetate/hexanes as effluent to give OP 4 (0.38 mmol, 83%). Analogous procedures were used for 12 other O-aryl alkylphosphonates (Supplementary Table 1).
11. 14C]1-oleoylglyerol (Supplementary data).
12. Quistad G.B., Liang S.N., Fisher K.J., Nomura D.K., and Casida J.E. Toxicol. Sci. 91 (2006) 166
13. 4
14. Kunos G., and Osei-Hyiaman D. Am. J. Physiol. Gastrointest. Liver Physiol. 294 (2008) G1101
15. Serhan C.N., Chiang N., and Van Dyke T.E. Nat. Rev. Immun. 8 (2008) 349
16. Cipollone F., Cicolini G., and Bucci M. Pharmacol. Ther. 118 (2008) 161
17. Wang D., and DuBois R.N. Cancer Lett. 3 (2008) 4 10.1016/j.canlet.2008.03.004
18. 4
19. Rosenberger T.A., Villacreses N.E., Contreras M.A., Bonventre J.V., and Rapoport S.I. J. Lipid Res. 44 (2003) 109
20. Farooqui A.A., Horrocks L.A., and Farooqui T. J. Neurochem. 101 (2007)
21. Abood M.E., Ditto K.E., Noel M.A., Showalter V.M., and Tao Q. Biochem. Pharmacol. 53 (1997) 207
22. 3H]CP55940 binding and sensitivity to WIN55212-2. Upon addition of brain membranes to eCB1, OP 7-sensitivity was partially restored.
23. max (pmol/mg) 0.27 for control and 0.26 for OP 7.
24. 50 of CB1 agonist binding.
25. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. Biochem. Biophys. Res. Commun. 215 (1995) 89
26. Upon consideration of the 2-AG concentration in a typical CB1 binding assay, controls would have 16 nM compared to 360 nM in brain membranes from OP 1-treated mice, consistent with the 2-AG levels required to induce stimulation of GTP binding.
27. Dainese E., Oddi S., Bari M., and Maccarrone M. Curr. Med. Chem. 14 (2007) 2702